Sp947
MEDICAL MANAGEMENT OF GASTROPARESIS
Date
May 20, 2024
Presenter
Mayo Clinic College of Medicine
Tracks
Related Products
ABNORMAL GI MOTILITY IS A MAJOR FACTOR IN EXPLAINING SYMPTOMS IN PATIENTS WITH DGBI
A session focusing on recent advances in our understanding of the complex pathophysiology of disorders of gut-brain interaction (DGBI)…
EFFECTS OF THE FGF-19 ANALOG ALDAFERMIN ON BILE ACID SYNTHESIS AND EXCRETION AND BOWEL FUNCTION IN PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME AND BILE ACID MALABSORPTION: A RANDOMIZED PLACEBO-CONTROL TRIAL
Ageing seems to have a beneficial effect on irritable bowel syndrome (IBS) (Sperber et al. Gastroenterology 2021), and the odds of developing IBS are lower when age is above 50 years (Lovell & Ford CGH 2012). Older age may also affect symptom reporting and quality of life…
THE CLINICAL VALUE OF BIOMARKER-BASED APPROACHES FOR THE EVALUATION AND MANAGEMENT OF IRRITABLE BOWEL SYNDROME: PRICE VS. PRECISION
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology…
